We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.23% | 29.75 | 29.55 | 30.50 | 30.05 | 29.53 | 29.80 | 5,444,214 | 21:57:01 |
From May 2019 to May 2024
By Colin Kellaher
Roche Holding AG's (ROG.EB) Genentech unit Tuesday said a phase II study of Gazyva met its primary and key secondary endpoints in adults with the kidney disorder proliferative lupus nephritis.
Genentech said Gazyva in combination with standard of care showed enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year.
Gazyva also showed improved overall renal responses and serologic markers of disease activity compared to placebo, the company said.
Genentech said there are currently no FDA-approved therapies for lupus nephritis, a potentially life-threatening condition in which patients are at high risk for progressing to end-stage renal disease or death.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 11, 2019 07:10 ET (11:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
